News | November 06, 2025
Teva reports 11th consecutive quarter of growth
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Teva reported third quarter revenues of $4.5 billion, an increase of 3 per cent year-over-year.
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Kulzer has consolidated the production of its core product, artificial teeth, at its facility in Germany
Upon completion, Kimberly-Clark shareholders are expected to own about 54% of the combined entity, while Kenvue shareholders will hold the remaining 46%
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Capvaxive has recorded $530 million in cumulative sales over its first four quarters on the market
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
AstraZeneca to invest $50bn in manufacturing and R&D to support domestic sourcing
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
Subscribe To Our Newsletter & Stay Updated
